# Dupixent in Adults With Refractory Post-Burn Pruritus in an Ambulatory Clinic

> **NCT06226610** · PHASE2 · RECRUITING · sponsor: **Akron Children's Hospital** · enrollment: 46 (estimated)

## Conditions studied

- Pruritis

## Interventions

- **DRUG:** Dupilumab
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT06226610
- **Lead sponsor:** Akron Children's Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-11-21
- **Primary completion:** 2026-01-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 46 (ESTIMATED)
- **Last updated:** 2025-09-19

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06226610

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06226610, "Dupixent in Adults With Refractory Post-Burn Pruritus in an Ambulatory Clinic". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06226610. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*